Abstract
Serum antibodies IgM and IgG are elevated during COVID-19 to defend against viral attack. Atypical results such as negative and abnormally high antibody expression were frequently observed whereas the underlying molecular mechanisms are elusive. In our cohort of 144 COVID-19 patients, 3.5% were both IgM and IgG negative whereas 29.2% remained only IgM negative. The remaining patients exhibited positive IgM and IgG expression, with 9.3% of them exhibiting over 20-fold higher titers of IgM than the others at their plateau. IgG titers in all of them were significantly boosted after vaccination in the second year. To investigate the underlying molecular mechanisms, we classed the patients into four groups with diverse serological patterns and analyzed their two-year clinical indicators. Additionally, we collected 111 serum samples for TMTpro-based longitudinal proteomic profiling and characterized 1494 proteins in total. We found that the continuously negative IgM and IgG expression during COVID-19 were associated with mild inflammatory reactions and high T cell responses. Low levels of serum IgD, inferior complement 1 activation of complement cascades, and insufficient cellular immune responses might collectively lead to compensatory serological responses, causing overexpression of IgM. Serum CD163 was positively correlated with antibody titers during seroconversion. This study suggests that patients with negative serology still developed cellular immunity for viral defense, and that high titers of IgM might not be favorable to COVID-19 recovery.
Competing Interest Statement
Q.Z. and X.Y. are employees of Westlake Omics Inc. Y.Z. and T.G. are shareholders of Westlake Omics Inc. The remaining authors declare no competing interests.
Funding Statement
This work was supported by grants from National Key R&D Program of China (2021YFA1301602, 2020YFE0202200), National Natural Science Foundation of China (81972492, 21904107, 82072333), Zhejiang Provincial Natural Science Foundation for Distinguished Young Scholars (LR19C050001), Hangzhou Agriculture and Society Advancement Program (20190101A04), Medical Science and Technology Project of Zhejiang Province (2021KY394), Westlake Education Foundation, and Scientific Research Foundation of Taizhou Enze Medical Center (Group) (21EZZX01).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study has been approved by the Ethical/Institutional Review Board of Westlake University and Taizhou Hospital (approval notice: K20210218). The studies in this work abide by the Declaration of Helsinki principles. Since archived specimens were used, informed consent from the patients was waived by the boards.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Patient information and serology data are available in the supplementary material. The proteomic raw data are deposited in ProteomeXchange Consortium (https://www.iprox.cn/page/PSV023.html;?url=1660551727880pH06, password: VcQ7).
https://www.iprox.cn/page/PSV023.html;?url=1660551727880pH06
Abbreviations
- ADE
- antibody-dependent enhancement;
- ARDS
- acute respiratory distress syndrome;
- C1
- complement 1;
- CLIA
- chemiluminescence immunoassay;
- COVID-19
- Coronavirus Disease 2019;
- CV
- coefficient of variation;
- DDA
- data-dependent acquisition;
- DEP
- differentially expressed protein;
- EHR
- electronic hospital record;
- HDL-C
- high-density lipoprotein cholesterol;
- IQR
- interquartile range;
- LDL-C
- low-density lipoprotein cholesterol;
- LOESS
- locally weighted scatterplot smoothing Nab, neutralizing antibody;
- nonVac
- non-vaccinated;
- PCA
- principal component analysis;
- R1
- one-year revisit;
- R2
- two-year revisit;
- RBD
- receptor binding domain;
- RLU
- relative luminescence unit;
- RT-PCR
- reverse-transcriptase polymerase-chain-reaction;
- TC
- total cholesterol;
- TEAB
- triethylammonium bicarbonate;
- TG
- triglyceride;
- TMT
- tandem mass tag;
- Vac
- vaccinated.
